Ueoka H, Kuroda S, Ohnoshi T, Kimura I, Numoto A, Hino I, Takahashi M, Tsuji M
Gan To Kagaku Ryoho. 1984 Dec;11(12 Pt 1):2579-84.
Six patients with hepatocellular carcinoma (HCC) and 9 patients with metastatic liver carcinoma (MLC) (4 with stomach cancer, 4 with pancreas cancer and 1 with colon cancer) were treated with rapid hepatic artery infusion of adriamycin. Partial response was obtained in 3 patients (44%) with HCC and 2 patients (22%) with MLC. The median survival time was 6 months in HCC patients and 8 months in MLC patients. Patients with elevated serum alkaline phosphatase or those with ascites were poorly prognostic. Myelosuppressive toxicity was seen frequently, but, no life-threatening complications occurred. Other toxicities were generally mild and well tolerated. These results indicated that hepatic artery infusion of adriamycin is a useful treatment modality in the management of both HCC and MLC.
6例肝细胞癌（HCC）患者和9例转移性肝癌（MLC）患者（4例胃癌、4例胰腺癌和1例结肠癌）接受了阿霉素肝动脉快速灌注治疗。3例（44%）HCC患者和2例（22%）MLC患者获得部分缓解。HCC患者的中位生存时间为6个月，MLC患者为8个月。血清碱性磷酸酶升高的患者或有腹水的患者预后较差。骨髓抑制毒性常见，但未发生危及生命的并发症。其他毒性一般较轻，耐受性良好。这些结果表明，阿霉素肝动脉灌注是治疗HCC和MLC的一种有效治疗方式。
